These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20025035)

  • 21. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.
    Kanai A; Zabbarova I; Oefelein M; Radziszewski P; Ikeda Y; Andersson KE
    Neurourol Urodyn; 2012 Mar; 31(3):300-8. PubMed ID: 22275187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms.
    Andersson KE
    Int J Clin Pract Suppl; 2006 Dec; (151):8-16. PubMed ID: 17169005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of action of intravesical botulinum treatment in refractory detrusor overactivity.
    Drake MJ
    BJU Int; 2008 Jul; 102 Suppl 1():11-6. PubMed ID: 18665973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability.
    Jung SY; Fraser MO; Ozawa H; Yokoyama O; Yoshiyama M; De Groat WC; Chancellor MB
    J Urol; 1999 Jul; 162(1):204-12. PubMed ID: 10379788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local effects of antimuscarinics.
    Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The physiological function of lower urinary tract smooth muscle.
    Fry CH; Meng E; Young JS
    Auton Neurosci; 2010 Apr; 154(1-2):3-13. PubMed ID: 19939745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder.
    Yoshida M; Masunaga K; Nagata T; Yono M; Homma Y
    J Pharmacol Sci; 2010; 112(2):128-34. PubMed ID: 20134115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spontaneous Activity and the Urinary Bladder.
    Fry CH; McCloskey KD
    Adv Exp Med Biol; 2019; 1124():121-147. PubMed ID: 31183825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
    Andersson KE; Yoshida M
    Eur Urol; 2003 Jan; 43(1):1-5. PubMed ID: 12507537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient controlled versus automatic stimulation of pudendal nerve afferents to treat neurogenic detrusor overactivity.
    Opisso E; Borau A; Rodríguez A; Hansen J; Rijkhoff NJ
    J Urol; 2008 Oct; 180(4):1403-8. PubMed ID: 18710774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical compounds for the treatment of overactive bladder.
    Giannitsas K; Konstantinopoulos A; Patsialas C; Athanasopoulos A; Perimenis P
    Expert Opin Ther Pat; 2009 Feb; 19(2):107-17. PubMed ID: 19441912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats.
    Behr-Roussel D; Oger S; Caisey S; Sandner P; Bernabé J; Alexandre L; Giuliano F
    Eur Urol; 2011 Feb; 59(2):272-9. PubMed ID: 21036463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sensory bladder (1): an update on the different sensations described in the lower urinary tract and the physiological mechanisms behind them.
    Wyndaele JJ; De Wachter S
    Neurourol Urodyn; 2008; 27(4):274-8. PubMed ID: 17880015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.
    Oger S; Behr-Roussel D; Gorny D; Denys P; Lebret T; Alexandre L; Giuliano F
    Eur Urol; 2007 Mar; 51(3):772-80; discussion 780-1. PubMed ID: 17097801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Terminology and Pathophysiology of Overactive Bladder (OAB)].
    Höfner K
    Aktuelle Urol; 2016 Dec; 47(6):468-474. PubMed ID: 27598780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
    Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
    BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caffeine ingestion causes detrusor overactivity and afferent nerve excitation in mice.
    Kershen R; Mann-Gow T; Yared J; Stromberg I; Zvara P
    J Urol; 2012 Nov; 188(5):1986-92. PubMed ID: 22999550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic receptor targets for lower urinary tract dysfunction.
    Yoshimura N; Kaiho Y; Miyazato M; Yunoki T; Tai C; Chancellor MB; Tyagi P
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):437-48. PubMed ID: 18034230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bladder distension and activation of the efferent function of sensory fibres: similarities with the effect of capsaicin.
    Lecci A; Giuliani S; Tramontana M; Santicioli P; Criscuoli M; Dion S; Maggi CA
    Br J Pharmacol; 1998 May; 124(2):259-66. PubMed ID: 9641541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic perspective on the physiology of the lower urinary tract.
    Andersson KE; Hedlund P
    Urology; 2002 Nov; 60(5 Suppl 1):13-20; discussion 20-1. PubMed ID: 12493344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.